SUPRAME Trial Propels the Development of TCR-Based Therapy in Cutaneous Melanoma: With Jason Luke, MD
Season 13, Episode 50, Aug 25, 10:15 PM
Share
Subscribe
Dr Luke discusses the rationale for evaluating IMA203 in cutaneous melanoma and what the PRAME trial findings may mean for the future of TCR therapy.
In today’s episode, supported by Immatics, we spoke with Jason Luke, MD, about the development of the PRAME-directed T-cell receptor (TCR) T-cell therapy IMA203 in the ongoing phase 3 SUPRAME trial (NCT06743126) in patients with previously treated, unresectable or metastatic cutaneous melanoma.
In our conversation, Dr Luke discussed the rationale for evaluating IMA203 in patients with cutaneous melanoma, the mechanism of action of this novel drug, the design of this study, earlier data that support the continued investigation of this agent in this population, and what these findings may mean for the future of TCR therapy in melanoma.
In our conversation, Dr Luke discussed the rationale for evaluating IMA203 in patients with cutaneous melanoma, the mechanism of action of this novel drug, the design of this study, earlier data that support the continued investigation of this agent in this population, and what these findings may mean for the future of TCR therapy in melanoma.